Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: The role of viral membrane fusion activity

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Budimir, Natalija ^a   Huckriede, Anke ^a   Meijerhof, Tjarko ^a   Boon, Louis ^b   Gostick, Emma ^c   Price, David A ^c   Wilschut, Jan ^a   de Haan, Aalzen ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BIOCEROS   (Netherlands)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME; INFLUENZA VACCINE; ANTISERUM; FORMALDEHYDE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; PROPIOLACTONE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PROTECTION; CYTOTOXIC T LYMPHOCYTE; ENZYME SYNTHESIS; FEMALE; INFECTION RESISTANCE; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MEMBRANE FUSION; MOUSE; NONHUMAN; T CELL DEPLETION; VIRUS ENVELOPE; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; DRUG EFFECT; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; LUNG; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; SPECIES DIFFERENCE; SURVIVAL; VACCINATION; VIROLOGY; VIRUS ENTRY; VIRUS INACTIVATION; VIRUS LOAD;

MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BODY WEIGHT; CROSS PROTECTION; FORMALDEHYDE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNE SERA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; PROPIOLACTONE; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, INACTIVATED; VIRAL LOAD; VIRUS INACTIVATION; VIRUS INTERNALIZATION;

EID: 84856377947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030898     Document Type: Article

References (51)

1. Nicholson KG, Wood JM, Zambon M, (2003) Influenza. Lancet 362: 1733-1745.
2. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD, (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61: 94-99.
3. Doherty PC, Turner SJ, Webby RG, Thomas PG, (2006) Influenza and the challenge for immunology. Nat Immunol 7: 449-455.
4. Doherty PC, Kelso A, (2008) Toward a broadly protective influenza vaccine. J Clin Invest 118: 3273-3275.
5. Taylor PM, Askonas BA, (1986) Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58: 417-420.
6. Epstein SL, (2003) Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti Infect Ther 1: 627-638.
7. Yewdell JW, Bennink JR, Smith GL, Moss B, (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82: 1785-1789.
8. Schotsaert M, Ibanez LI, Fiers W, Saelens X, (2010) Controlling influenza by cytotoxic T-cells: calling for help from destroyers. J Biomed Biotechnol 2010: 863985.
9. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, et al. (2007) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One 2: e1190.
10. Budimir N, Meijerhof T, Wilschut J, Huckriede A, de Haan A, The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes. Vaccine 28: 8280-8287.
11. Blackburn NK, Besselaar TG, (1991) A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J Virol Methods 33: 367-374.
12. Murphy BR, Walsh EE, (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26: 1595-1597.
13. Rock KL, Shen L, (2005) Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 207: 166-183.
14. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, et al. (2006) Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117: 78-88.
15. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, et al. (2005) The virosome concept for influenza vaccines. Vaccine 23 (Suppl 1): S26-38.
16. Hu AY, Tseng YF, Weng TC, Liao CC, Wu J, et al. (2011) Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One 6: e14578.
17. Nabel GJ, Fauci AS, (2010) Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 16: 1389-1391.
18. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
19. Sandbulte MR, Jimenez GS, Boon ACM, Smith LR, Treanor JJ, et al. (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4: 265-272.
20. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL, (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 84: 9217-9226.
21. Townsend AR, Skehel JJ, (1982) Influenza A specific cytotoxic T-cell clones that do not recognize viral glycoproteins. Nature 300: 655-657.
22. Townsend AR, Skehel JJ, (1984) The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 160: 552-563.
23. Bennink JR, Yewdell JW, Gerhard W, (1982) A viral polymerase involved in recognition of influenza virus-infected cells by a cytotoxic T-cell clone. Nature 296: 75-76.
24. de Jonge J, Holtrop M, Wilschut J, Huckriede A, (2006) Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther 13: 400-411.
25. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C, (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
26. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, et al. (2008) Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 4: e1000138.
27. Wagner H, Heit A, Schmitz F, Bauer S, (2004) Targeting split vaccines to the endosome improves vaccination. Curr Opin Biotechnol 15: 538-542.
28. Wagner H, (2009) The immunogenicity of CpG-antigen conjugates. Adv Drug Deliv Rev 61: 243-247.
29. Fonteneau JF, Gilliet M, Larsson M, Dasilva I, Munz C, et al. (2003) Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 101: 3520-3526.
30. Amigorena S, Savina A, (2010) Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 22: 109-117.
31. Gromme M, Neefjes J, (2002) Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 39: 181-202.
32. Ackerman AL, Cresswell P, (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5: 678-684.
33. Bender A, Bui LK, Feldman MA, Larsson M, Bhardwaj N, (1995) Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med 182: 1663-1671.
34. McMichael AJ, Gotch FM, Noble GR, Beare PA, (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17.
35. Furuya Y, Chan J, Regner M, Lobigs M, Koskinen A, et al. (2010) Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. J Virol 84: 4212-4221.
36. Bodewes R, Kreijtz JH, Hillaire ML, Geelhoed-Mieras MM, Fouchier RA, et al. (2010) Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol 91: 1743-1753.
37. Combadiere B, Vogt A, Mahe B, Costagliola D, Hadam S, et al. (2010) Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS One 5: e10818.
38. Coutsinos Z, Villefroy P, Gras-Masse H, Guillet JG, Bourgault-Villada I, (2005) Evaluation of SIV-lipopeptide immunizations administered by the intradermal route in their ability to induce antigen specific T-cell responses in rhesus macaques. FEMS Immunol Med Microbiol 43: 357-366.
39. Settembre EC, Dormitzer PR, Rappuoli R, (2011) Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. J Mol Cell Biol 3: 144-146.
40. Dormitzer PR, Galli G, Castelino F, Golding H, Khurana S, et al. (2011) Influenza vaccine immunology. Imm Rev 239: 167-177.
41. Cao B, Li XW, Mao Y, Wang J, Lu HZ, et al. (2009) Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 361: 2507-2517.
42. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106: 20365-20370.
43. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478-3490.
44. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161-5166.
45. Couch RB, (2011) Lessons learned from clinical trials in 1976 and 1977 of vaccines for the newly emerged swine and Russian influenza A/H1N1 viruses. In: Rappuoli R, Del Guidice G, editors. Influenza vaccines for the future pp. 359-363 Springer: Basel.
46. European Pharmacopeia 01/2005:0158. Influenza vaccine (split virion, inactivated).
47. Geeraedts F, Saluja V, ter Veer W, Amorij JP, Frijlink HW, et al. (2010) Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS J 12: 215-222.
48. Hanon EJ, Stephenne J, (2008) United States patent application publication: US 2008/0014217 A1.
49. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, et al. (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26: 2350-2359.
50. Oxford JS, Corcoran T, Hugentobler AL, (1981) Quantitative analysis of the protein composition of influenza A and B viruses using high resolution SDS polyacrylamide gels. J Biol Stand 9: 483-491.
51. Price DA, Brenchley JM, Ruff LE, Betts MR, Hill BJ, et al. (2005) Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med 202: 1349-1361.